YouTube Facebook LinkedIn Google+ Twitter Xingrss  

Phase II Flub for Peregrine


September 24, 2012 | A week after releasing favorable Phase II results for the novel vascular-targeting immunotherapy for non-small cell lung cancer, bavituximab, study sponsor Peregrine Pharmaceuticals has announced "major discrepancies" in the trial. Peregrine blames the research oversight team in charge of the trial (they were blinded), but the announcement still resulted in plummeting Peregrine stock. Cancer Grace
View Next Related Story
Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1


For reprints and/or copyright permission, please contact  Terry Manning, 781.972.1349 , tmanning@healthtech.com.